Literature DB >> 17390110

CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy.

Guorong Li1, Gang Feng, Anne Gentil-Perret, Christian Genin, Jacques Tostain.   

Abstract

About 30-40% of patients with renal cell carcinoma (RCC) will develop metastasis after curative nephrectomy. There is a strong need to identify the early metastasis with conventional and molecular risk factors. The present study aimed to test if analysis of the CA9 gene can provide useful information to predict early metastasis after nephrectomy. This study included 63 patients with a conventional RCC. Ten tumors were N+ or/and M+ at diagnosis. The mean follow-up was 43 months (range, 4-67 months). About 11 M0N0 patients were found to have a metastasis during the follow-up. Quantitative RT-PCR of CA9 gene expression was performed. The metastasis-free survival curve was established according to the Kaplan-Meier method with comparison by the Log-Rank test. At diagnosis, the average of CA9 gene expression was significantly lower (p = 0.004) in metastatic tumors (N+ or/and M+) than in non-metastatic tumors (N0M0). For the follow-up of M0N0 patients, the metastasis-free survival rate was significantly higher (p = 0.005) in the high CA9 group than in the low-CA9 group. When combined with CA9, the metastasis-free survival rates, in terms of stage (p = 0.015) or grade (p = 0.010) were significantly different. When the stage, grade, and CA9 were combined, there was a significant difference (p = 0.004) in metastasis-free survival rates (T1T2 + G1G2 + high expression of CA9 versus T3 + G3G4 + low expression of CA9). Finally, the multivariate regression analysis identified CA9 expression (p = 0.036) as an independent predictor of early metastasis. Our study confirms that the expression level of CA9 gene in conventional RCC is related to metastasis. CA9 may be a potential marker for the prediction of early metastasis after nephrectomy and to guide post-operative follow-up and treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390110     DOI: 10.1007/s10585-007-9064-z

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  28 in total

Review 1.  [Follow-up of renal cancer. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie].

Authors:  Jean-Philippe Fendler; Jean-Jacques Patard; Arnaud Mejean; Jean-Louis Davin
Journal:  Prog Urol       Date:  2005-09       Impact factor: 0.915

2.  Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.

Authors:  Michael I Koukourakis; Søren M Bentzen; Alexandra Giatromanolaki; George D Wilson; Frances M Daley; Michele I Saunders; Stanley Dische; Efthimios Sivridis; Adrian L Harris
Journal:  J Clin Oncol       Date:  2006-01-17       Impact factor: 44.544

3.  Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma.

Authors:  J M McKiernan; R Buttyan; N H Bander; M D Stifelman; A E Katz; M W Chen; C A Olsson; I S Sawczuk
Journal:  Cancer Res       Date:  1997-06-15       Impact factor: 12.701

4.  Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.

Authors:  Joonas A Haapasalo; Kristiina M Nordfors; Mika Hilvo; Immo J Rantala; Ylermi Soini; Anna-Kaisa Parkkila; Silvia Pastoreková; Jaromir Pastorek; Seppo M Parkkila; Hannu K Haapasalo
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

5.  Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Authors:  Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

6.  Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma.

Authors:  Kårstein Måseide; Rita A Kandel; Robert S Bell; Charles N Catton; Brian O'Sullivan; Jay S Wunder; Melania Pintilie; David Hedley; Richard P Hill
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

7.  Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas.

Authors:  Ann Driessen; Willy Landuyt; Sylvia Pastorekova; Johnny Moons; Laurence Goethals; Karin Haustermans; Philippe Nafteux; Freddy Penninckx; Karel Geboes; Toni Lerut; Nadine Ectors
Journal:  Ann Surg       Date:  2006-03       Impact factor: 12.969

8.  Rapid and sensitive detection of messenger RNA expression for molecular differential diagnosis of renal cell carcinoma.

Authors:  Guorong Li; Muriel Cuilleron; Anne Gentil-Perret; Michèle Cottier; Karine Passebosc-Faure; Claude Lambert; Christian Genin; Jacques Tostain
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

9.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

10.  Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas.

Authors:  A Tchirkov; C Rolhion; J-L Kémény; B Irthum; S Puget; T Khalil; O Chinot; F Kwiatkowski; B Périssel; P Vago; P Verrelle
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

View more
  6 in total

Review 1.  The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.

Authors:  Sunao Shoji; Mayura Nakano; Haruhiro Sato; Xian Yang Tang; Yoshiyuki Robert Osamura; Toshiro Terachi; Toyoaki Uchida; Koichi Takeya
Journal:  Clin Exp Metastasis       Date:  2014-01       Impact factor: 5.150

2.  Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant.

Authors:  Yanping Wang; Xiang-Yang Wang; John R Subjeck; Hyung L Kim
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

3.  Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.

Authors:  A Ingels; M Hew; F Algaba; O J de Boer; R J A van Moorselaar; S Horenblas; P Zondervan; J J M C H de la Rosette; M Pilar Laguna Pes
Journal:  World J Urol       Date:  2016-05-20       Impact factor: 4.226

4.  Role of CAIX Expression in Conventional Renal Cell Carcinomas as a Diagnostic Marker and its Prognostic Importance.

Authors:  Kavitha Ramachandran; Bindhu M R; Annie Jojo; Ginil Kumar Pooleri; Appu Thomas
Journal:  Indian J Surg Oncol       Date:  2020-07-20

5.  Optimization of a novel peptide ligand targeting human carbonic anhydrase IX.

Authors:  Shoaib Rana; Felix Nissen; Annabell Marr; Annette Markert; Annette Altmann; Walter Mier; Juergen Debus; Uwe Haberkorn; Vasileios Askoxylakis
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

6.  Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.

Authors:  Zhihong Zhao; Guixiang Liao; Yongqiang Li; Shulu Zhou; Hequn Zou; Samitha Fernando
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.